Download PDF
Thromb Haemost 1977; 38(04): 0900-0908
DOI: 10.1055/s-0038-1651908
Original Article
Schattauer GmbH

Spurious Prolongation of the Activated Partial Thromboplastin Time

Robert A. Okpara
1   Section of Hematology, Department of Medicine and Thrombosis Research Center of Temple University School of Medicine, Philadelphia, Penna, U.S.A.
,
Joann Carabello
1   Section of Hematology, Department of Medicine and Thrombosis Research Center of Temple University School of Medicine, Philadelphia, Penna, U.S.A.
,
H James Day
1   Section of Hematology, Department of Medicine and Thrombosis Research Center of Temple University School of Medicine, Philadelphia, Penna, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
04 July 2018 (online)

    Permissions and Reprints

Summary

The clinical and laboratory data of 8 patients (4 males and 4 females) with circulating anticoagulant were presented. Based on prolonged APTT, failure to correct the APTT with 50 % normal plasma and abnormal tissue thromboplastin inhibition test, the inhibitor was identified as “middle stage” – or the “lupus anticoagulant”. Thrombokinetics showed the maximal rate of change in optical density (VmaxΔOD) of plasma, resulting from clot formation to be significantly less in the plasma of patients with the inhibitor than in normal plasma. This was not completely corrected by mixing the patients’ plasma with 50% normal plasma.

 

  • References

  • 1 Abraham J. P, Ututin O. N, Johnson S. A, Caldwell J. 1961; A study of the defects in the blood coagulation mechanisms in polycythemia vera. American Journal of Clinical Pathology 36: 7.
    CrossrefPubMedGoogle Scholar
  • 2 Bowie E. W, Thompson J. Y, Cascuzzi P. A, Owen G. A. 1963; Thrombosis in SLE despite circulating anticoagulants. Journal of Laboratory and Clinical Medicine 62: 416.
    PubMedGoogle Scholar
  • 3 Conley C. L, Hartmann R. C. 1952; A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated Lupus Erythematosus. Journal of Clinical Investigation 31: 621.
    PubMedGoogle Scholar
  • 4 Donaldson V. H. et al. 1976; Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in the clotting and fibrinolysis. Journal of Laboratory and Clinical Medicine 87 (02) 327.
    PubMedGoogle Scholar
  • 5 Feinstein D. J, Rapaport S. I. 1972; Acquired inhibitors of blood coagulation. Progressin Hemostasis and Thrombosis 1: 75.
    PubMedGoogle Scholar
  • 6 Green D. 1972; Circulating anticoagulants. Medical Clinics of North America 56: 145.
    CrossrefPubMedGoogle Scholar
  • 7 Hathway W. E, Belhasen L. P, Hethnay H. S. 1965; Evidence for a new plasma thromboplastin I. Case Report. Coagulation Studies and Physicochemical Properties. Blood 26: 521.
    PubMedGoogle Scholar
  • 8 Karaca M, Stefanini M. 1967; Thromboplastic activity and content in lipids and phospholipids of platelets in polycythemia vera with associated thrombocytopathy. American Journal of Clinical Pathology 48: 320.
    CrossrefPubMedGoogle Scholar
  • 9 Lechner K. 1974; Acquired inhibitors in non-hemophilic patients. Hemostasis 3: 65.
    PubMedGoogle Scholar
  • 10 Lechner K. 1969; A new type of coagulation inhibitor. Thrombosis et Diathesis Haemorrhagica 21: 482.
    PubMedGoogle Scholar
  • 11 Loeliger A. 1959; Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thrombosis et Diathesis Haemorrhagica 3: 327.
    PubMedGoogle Scholar
  • 12 Medal L. S, Lisker R. 1959; Circulating anticoagulants in disseminated Lupus Erythematosus. British Journal of Hematology 5: 284.
    CrossrefPubMedGoogle Scholar
  • 13 Natelson E. A, Dooley D. F. 1974; Rapid determination of fibrinogen by thrombokinetics. American Journal of Clinical Pathology 61: 628.
    CrossrefPubMedGoogle Scholar
  • 14 Natelson E. A, Shapiro D, Smith D. F. 1975; Detection of mild factor VIII deficiency by thrombokinetics. American Journal of Clinical Pathology 64: 95.
    CrossrefPubMedGoogle Scholar
  • 15 Rapaport S. L, Ames S. B, Duvall B. J. 1960; A plasma coagulation defect in Systemic Lupus Erythematosus arising from hypoprothrombinemia combined with anti-thrombinase activity. Blood 15: 212.
    PubMedGoogle Scholar
  • 16 Ratnoff O. D, Colopy J. E. 1955; A familial hemorrhagic trait associated with a deficiency of a clotpromoting fraction of plasma. Journal of Clinical Investigation 34: 602.
    CrossrefPubMedGoogle Scholar
  • 17 Regan M. G. et al. 1974; Platelet function and coagulation profile in Lupus Erythematosus: Studies in 50 cases. Annals of Internal Medicine 81: 462.
    CrossrefPubMedGoogle Scholar
  • 18 Rivard A. E, Schiffman S, Rapaport S. I. 1974; Co-factor of the “Lupus Anticoagulants”. Thrombosis et Diathesis Haemorrhagica 32: 554.
    PubMedGoogle Scholar
  • 19 Saito H, Ratnoff O. D, Waldmann R. et al. 1976; Fitzgerald trait. Journal of Clinical Investigation 55: 1082.
    PubMedGoogle Scholar
  • 20 Schleider M. A. et al. 1976; Clinical study of the lupus anticoagulant. Blood 48: 499.
    PubMedGoogle Scholar
  • 21 Yin E. T, Gaston L. W. 1965; Purification and kinetic studies on circulating anticoagulant in a suspected case of lupus erythematosus. Thrombosis et Diathesis Haemorrhagica 14: 88.
    PubMedGoogle Scholar